Magnus is an AI-powered, fully automated lab platform that designs, generates, and validates programmable ligands—turning PFAS, toxins, and high-value targets into deployable detection and capture assets in weeks.
Built for high-consequence environments: defense · infrastructure · food · industrial biotech
Detection is now an everywhere problem—air, water, food lines, manufacturing, forward operating environments. But the hardest part hasn't scaled: the molecular receptor layer. Magnus makes it scalable.
Not "research projects." Production outputs.
Because buyers don't buy one analyte. They buy coverage.
Magnus doesn't stop at binders. It delivers integration-ready assets.
From automated selection to validated ligands—witness the platform that's industrializing molecular recognition.
Parallel selection lanes running 24/7 with robotic precision—no human variability, no bottlenecks.
Sequencing-driven enrichment intelligence that identifies winners early.
Quantified affinity, specificity panels, and cross-reactivity maps—not guesses.
Coverage is the product—PFAS panels, toxin panels, with expansion roadmaps built in.
Reproducibility, traceability, and audit-ready reports from day one.
Magnus runs a closed loop where automation executes experiments and AI guides iteration—so each cycle gets faster, cleaner, and more predictive.
Strategy, negative selections, validation plan
Parallel automated lanes with controls
Sequencing + validation + specificity
Enrichment analytics + decision models
Asset sheets, pilot kits, panel roadmaps
PFOA/PFOS plus expanded PFAS coverage. Built to deliver clear cross-reactivity maps and matrix behavior—so your team can act, not debate.
Rapid panel generation with evaluation-grade evidence packages. Designed to update as threat lists change.
Magnus is the receptor supply chain for the next generation of biotech.
Parallel throughput, less human variability
Reproducibility, traceability, external-ready reporting
Coverage is the product, not a single target
Every run improves the system
Start with a pilot. Leave with validated programmable ligands and a path to scale.